Merck's weekly diabetes drug measures up to an old blockbuster in Phase III

Merck's ($MRK) once-a-week omarigliptin proved itself equal to Januvia, stacking up to a daily treatment that brought in about $3.9 billion for the company last year. In a Phase III study on 642 adults with Type 2 diabetes, a weekly dose of Januvia charted a similar effect on average blood glucose as daily Januvia administration, Merck said. The two drugs, which work by blocking a protein called DPP-4, charted similar safety profiles in the study, according to the company, and both had similar rates of adverse events as the placebo arm. Merck is now on track to file omarigliptin for FDA approval by the end of 2015, the company said, and it has already submitted the new treatment in Japan. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.